GKOSGLAUKOS Corp
Surgical & Medical Instruments & Apparatus
- Revenue
- $507M
- 32% YoY
- Operating margin
- -39.3%
- 23% YoY
- EBITDA
- −$162M
- 86% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$159M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired12% of revenueOver 10% of revenue
- Payouts exceed cash flowClear-1% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear7% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $294M | $283M | $315M | $383M | $507M | 32% |
| Operating income | −$33M | −$82M | −$129M | −$122M | −$200M | 63% |
| Net income | −$50M | −$99M | −$135M | −$146M | −$188M | 28% |
| Operating cash flow | $25M | −$33M | −$58M | −$61M | −$15M | 76% |
| Capex | $48M | $30M | $20M | $6M | $8M | 22% |
| Stock-based comp | $30M | $39M | $44M | $50M | $63M | 26% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $743K · 14
- Net
- −$743K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $12M | $10M | 150 | 78 |
| FY2024 | $9M | $25M | 199 | 78 |
| FY2023 | $9M | $22M | 106 | 76 |
| FY2022 | $6M | $5M | 58 | 78 |
| FY2021 | $7M | −$173K | 59 | 106 |